Cargando…

Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications

Immunotherapy has reached clinical success in the last decade, with the emergence of new and effective treatments such as checkpoint blockade therapy and CAR T-cell therapy that have drastically improved patient outcomes. Still, these therapies can be improved to limit off-target effects, mitigate s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuang, Skylar T., Conklin, Brandon, Stein, Joshua B., Pan, George, Lee, Ki-Bum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047473/
https://www.ncbi.nlm.nih.gov/pubmed/35482149
http://dx.doi.org/10.1186/s40580-022-00310-0
_version_ 1784695734222716928
author Chuang, Skylar T.
Conklin, Brandon
Stein, Joshua B.
Pan, George
Lee, Ki-Bum
author_facet Chuang, Skylar T.
Conklin, Brandon
Stein, Joshua B.
Pan, George
Lee, Ki-Bum
author_sort Chuang, Skylar T.
collection PubMed
description Immunotherapy has reached clinical success in the last decade, with the emergence of new and effective treatments such as checkpoint blockade therapy and CAR T-cell therapy that have drastically improved patient outcomes. Still, these therapies can be improved to limit off-target effects, mitigate systemic toxicities, and increase overall efficacies. Nanoscale engineering offers strategies that enable researchers to attain these goals through the manipulation of immune cell functions, such as enhancing immunity against cancers and pathogens, controlling the site of immune response, and promoting tolerance via the delivery of small molecule drugs or biologics. By tuning the properties of the nanomaterials, such as size, shape, charge, and surface chemistry, different types of immune cells can be targeted and engineered, such as dendritic cells for immunization, or T cells for promoting adaptive immunity. Researchers have come to better understand the critical role the immune system plays in the progression of pathologies besides cancer, and developing nanoengineering approaches that seek to harness the potential of immune cell activities can lead to favorable outcomes for the treatment of injuries and diseases.
format Online
Article
Text
id pubmed-9047473
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-90474732022-04-28 Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications Chuang, Skylar T. Conklin, Brandon Stein, Joshua B. Pan, George Lee, Ki-Bum Nano Converg Review Immunotherapy has reached clinical success in the last decade, with the emergence of new and effective treatments such as checkpoint blockade therapy and CAR T-cell therapy that have drastically improved patient outcomes. Still, these therapies can be improved to limit off-target effects, mitigate systemic toxicities, and increase overall efficacies. Nanoscale engineering offers strategies that enable researchers to attain these goals through the manipulation of immune cell functions, such as enhancing immunity against cancers and pathogens, controlling the site of immune response, and promoting tolerance via the delivery of small molecule drugs or biologics. By tuning the properties of the nanomaterials, such as size, shape, charge, and surface chemistry, different types of immune cells can be targeted and engineered, such as dendritic cells for immunization, or T cells for promoting adaptive immunity. Researchers have come to better understand the critical role the immune system plays in the progression of pathologies besides cancer, and developing nanoengineering approaches that seek to harness the potential of immune cell activities can lead to favorable outcomes for the treatment of injuries and diseases. Springer Nature Singapore 2022-04-28 /pmc/articles/PMC9047473/ /pubmed/35482149 http://dx.doi.org/10.1186/s40580-022-00310-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Chuang, Skylar T.
Conklin, Brandon
Stein, Joshua B.
Pan, George
Lee, Ki-Bum
Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
title Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
title_full Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
title_fullStr Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
title_full_unstemmed Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
title_short Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
title_sort nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047473/
https://www.ncbi.nlm.nih.gov/pubmed/35482149
http://dx.doi.org/10.1186/s40580-022-00310-0
work_keys_str_mv AT chuangskylart nanotechnologyenabledimmunoengineeringapproachestoadvancetherapeuticapplications
AT conklinbrandon nanotechnologyenabledimmunoengineeringapproachestoadvancetherapeuticapplications
AT steinjoshuab nanotechnologyenabledimmunoengineeringapproachestoadvancetherapeuticapplications
AT pangeorge nanotechnologyenabledimmunoengineeringapproachestoadvancetherapeuticapplications
AT leekibum nanotechnologyenabledimmunoengineeringapproachestoadvancetherapeuticapplications